Impel NeuroPharma launches Reroute Migraine Relief initiative » 08:0805/1805/18/21
Wedbush bullish on Impel NeuroPharma, initiates with an Outperform » 07:4705/1805/18/21
As previously reported,…
As previously reported, Wedbush analyst Laura Chico initiated coverage of Impel NeuroPharma with an Outperform rating and $21 price target. The analyst notes that drug delivery to the CNS represents a perennial problem, driving both safety and efficacy profiles. NeuroPharma's proprietary Precision Olfactory Delivery system seeks to overcome these challenges by delivering drugs to the upper nasal cavity, bypassing the blood-brain barrier, Chico says. Her prior Key Opinion Leaders conversations indicate favorable perceptions of DHE, with a desire for a more patient-friendly format. The analyst sees the company's Trudhesa fulfilling this profile and the 9/6/21 PDUFA as providing an important catalyst. Additionally, Chico views NeuroPharma's efforts aided by both physicians' underlying knowledge of DHE and the company's Phase 3 results.
Impel NeuroPharma initiated with an Outperform at Wedbush » 07:0005/1805/18/21
Wedbush analyst Laura…
Wedbush analyst Laura Chico initiated coverage of Impel NeuroPharma with an Outperform rating and $21 price target.
Impel NeuroPharma initiated with a Buy at Guggenheim » 06:3205/1805/18/21
Guggenheim analyst Dana…
|Over a week ago|
Impel NeuroPharma opens at $15.31, IPO priced at $15 per share » 11:5004/2304/23/21
Impel NeuroPharma (IMPL)…
Impel NeuroPharma (IMPL) priced 5.33M shares at $15.00. The deal priced at midpoint of $14.00-$16.00 range. Cowen and Guggenheim are acting as joint book running managers for the offering. Impel NeuroPharma is a late-stage pharmaceutical company focused on advancing its product candidate pipeline - which includes TRUDHESA for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson's disease - paired with its proprietary Precision Olfactory Delivery system.
Impel NeuroPharma 5.33M share IPO priced at $15.00 » 18:5104/2204/22/21
The deal priced at…
The deal priced at midpoint of $14.00-$16.00 range. Cowen and Guggenheim are acting as joint book running managers for the offering.